Stryker director sells beaucoup shares; Crowdfunding blunts device app regulatory demands;

@FierceMedDev: Enzymatics jumps into next-gen Dx space with $50M startup buy. More | Follow @FierceMedDev

@MarkHFierce: Better sanitation is linked to more Alzheimer's cases. Article | Follow @MarkHFierce

@MichaelGFierce: Myriad rolls out next-gen Dx for 8 major cancers. Story | Follow @MichaelGFierce

> A Stryker ($SYK) director has sold more than $1.4 million in shares of common stock. Story

> Makers of medical device apps are turning to crowdfunding to help support new demands created by FDA regulatory oversight. Story

> A new coating helped reduce the blood clot risk inside stents in an animal study. Item

> VirtualScopics ($VSCP) says it has regained compliance with the minimum $1 share bid price requirement for the Nasdaq stock market. The Rochester, NY, company makes imaging technology used for medical device and drug development. Item

> StelKast in Pennsylvania won the FDA's 510(k) clearance to market EXp, which is intended to boost the durability of its Proven Gen-Flex total knee system. Item

Biotech News

@FierceBiotech: In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. Article from FierceBiotech IT | Follow @FierceBiotech

@JohnCFierce: Crowdfunding cash for biotech startup Perle (diabetes). Press release | Follow @JohnCFierce

@Ry_McBride: UPDATED: No end of biotech IPO frenzy in sight. Special report | Follow @Ry_McBride

@EmilyMFierce: Making iPS cells safer for use in humans through the study of a cellular odd fellow. More from Stanford | Follow @EmilyMFierce

> Novartis strikes stem cell deal to aid transplant patients. Story

NYT: Blech says he could have been a biotech billionaire. Article

> Under FDA priority review, Mallinckrodt's pain med succeeds in PhIII. More

Pharma News

@FiercePharma: Glaxo said to be near $1.6B Lucozade-Ribena sale to Japan's Suntory. Latest in series of brand sales. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: Bristol-Myers Squibb flees high cost of East Coast with new center in Tampa, FL. Moving some jobs from NJ. Report | Follow @EricPFierce

@CarlyHFierce: Departure of new Vivus CEO Zook tops the list of this week's hirings, firings & other movements in pharma/biotech. Chutes & Ladders | Follow @CarlyHFierce

> Would GSK pull out of China altogether? More

> 'Doctor-2' in Elan, Wyeth insider trading case said to be well connected Alzheimer's doc. Article

> Another compounder recalls drugs because of lapse in outside testing. Story

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.